Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.

You may also be interested in...



Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting

FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.

Antigenics Oncophage On Hold After Phase III Failure, Conflicting Preliminary Data

Antigenics is shifting its focus to its Phase I and preclinical development programs following the failure of its therapeutic vaccine Oncophage in a Phase III renal cell carcinoma (RCC) trial, the company said

Cancer Trials Need New Endpoints For Progression, FDA Guidance Says

Cancer trials need new methods of measuring progression, FDA guidance says. Draft document on clinical trial endpoints for cancer drugs advocates survival as “gold standard,” but discusses value of progression assessment as potential surrogate marker

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel